Barinthus Biotherapeutics PLC (BRNS)
1.38
+0.06
(+4.55%)
USD |
NASDAQ |
Jun 25, 16:00
1.38
0.00 (0.00%)
After-Hours: 20:00
Barinthus Biotherapeutics Enterprise Value: -75.92M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | -75.92M |
| June 24, 2024 | -78.26M |
| June 21, 2024 | -78.26M |
| June 20, 2024 | -81.00M |
| June 18, 2024 | -66.55M |
| June 17, 2024 | -63.82M |
| June 14, 2024 | -58.36M |
| June 13, 2024 | -55.23M |
| June 12, 2024 | -55.62M |
| June 11, 2024 | -58.55M |
| June 10, 2024 | -55.62M |
| June 07, 2024 | -52.11M |
| June 06, 2024 | -55.82M |
| June 05, 2024 | -53.09M |
| June 04, 2024 | -56.02M |
| June 03, 2024 | -51.72M |
| May 31, 2024 | -55.23M |
| May 30, 2024 | -51.72M |
| May 29, 2024 | -48.21M |
| May 28, 2024 | -41.58M |
| May 24, 2024 | -43.52M |
| May 23, 2024 | -41.57M |
| May 22, 2024 | -40.01M |
| May 21, 2024 | -45.82M |
| May 20, 2024 | -36.15M |
| Date | Value |
|---|---|
| May 17, 2024 | -38.06M |
| May 16, 2024 | -34.94M |
| May 15, 2024 | -42.94M |
| May 14, 2024 | -39.23M |
| May 13, 2024 | -38.26M |
| May 10, 2024 | -38.65M |
| May 09, 2024 | -38.06M |
| May 08, 2024 | -41.18M |
| May 07, 2024 | -41.22M |
| May 06, 2024 | -43.56M |
| May 03, 2024 | -44.73M |
| May 02, 2024 | -46.10M |
| May 01, 2024 | -43.95M |
| April 30, 2024 | -49.80M |
| April 29, 2024 | -28.74M |
| April 26, 2024 | -32.25M |
| April 25, 2024 | -35.02M |
| April 24, 2024 | -31.86M |
| April 23, 2024 | -30.30M |
| April 22, 2024 | -27.56M |
| April 19, 2024 | -31.86M |
| April 18, 2024 | -24.05M |
| April 17, 2024 | -28.35M |
| April 16, 2024 | -31.08M |
| April 15, 2024 | -26.71M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-121.47M
Minimum
Dec 21 2022
423.44M
Maximum
May 17 2021
21.95M
Average
-37.10M
Median
Enterprise Value Benchmarks
| Achilles Therapeutics PLC | -75.25M |
| TC BioPharm (Holdings) PLC | 2.372M |
| Virax Biolabs Group Ltd | -2.926M |
| Adaptimmune Therapeutics PLC | 77.49M |
| Biodexa Pharmaceuticals Plc | 0.2994M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.49M |
| Total Expenses (Quarterly) | 16.32M |
| EPS Diluted (Quarterly) | -0.40 |
| Earnings Yield | -133.3% |
| Normalized Earnings Yield | -105.07 |